This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Achillion Hasn't Stopped Aching

NEW YORK (TheStreet) -- It would be a gross understatement to say that Achillion Pharmaceuticals (ACHN) has gone through some aches and pains.

After Achillion traded as high as $10.17 in February of last year, the stock tanked to $2.26 in October -- losing close to 80% in seven months. Investors were stunned by the news that the Food and Drug Administration, or FDA, opted to not remove sovaprevir, the company's lead protease inhibitor for hepatitis C, off clinical hold. The FDA wasn't convinced that the drug was safe.

I can't think of a better example than this to explain the pitfalls of investing in the biotech industry. It's known for some meaningful breakthroughs, yes. But it's also extremely volatile. This is a sector that moves quickly in either direction on the prospects of any new drug.

But investors have to realize that not all drugs are going to be blockbuster candidates. And without the right management and funding for research, the company may never get a product to market. This is regardless of how much "potential" investors believe they have. What's important to remember when betting on these drugs is that the FDA is known to say "over my dead body."

For Achillion, this has been the response. The good news is, since the stock bottomed at $2.26 last October, shares have been up by 53%. It's worth asking: What has been the catalyst, given that there's been very little progress with sovaprevir.

I will grant that the Street could have overreacted. That the stock took an 80%-pounding in seven months seems a bit extreme. Still, it's worth asking, should investors have speculated so highly on Achillion in the first place?

On Wednesday, when Achillion reports fourth-quarter results, management will try to convince the Street that this company is not the long shot that many investors believe it is. The way I see it, absent a clear and healthy pipeline update and an improvement in revenue, there won't be much about which to be excited.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,104.00 -9.54 -0.06%
S&P 500 1,988.64 +5.11 0.26%
NASDAQ 4,478.64 +22.6240 0.51%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs